In the new study, published online in the December issue of the journal Nature Medicine, VCU researchers, together with researchers from the Johns Hopkins Medical Institutions, have shown how the genetic element, known as progression elevated gene-3 promoter, or PEG-Prom, can be used to image metastases in multiple animal models of human melanoma and human breast metastasis. The system can be used to measure gene expression, protein interaction or track gene-tagged cells in vivo. This approach offers significant advantages in sensitivity and accuracy over currently used imaging strategies.
Novel therapy for metastatic kidney cancer developed at VCU Massey and VCU Institute for Molecular Medicine
Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus. Renal cell carcinoma is the most common form of kidney cancer in adults and currently there is no effective treatment for the disease once it has spread outside of the kidney.oma and brain, prostate, pancreatic, breast and colon cancers.
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
Researchers at Virginia Commonwealth University have discovered that a gene well known for its involvement in tumor cell development, growth and metastasis also protects cancer cells from being destroyed by chemotherapy. By inhibiting the expression of this gene, doctors may have a new viable and effective approach for treating aggressive cancers such as breast, liver and prostate carcinomas, malignant gliomas and neuroblastomas that result from high expression of this cancer-promoting gene.
Virginia Commonwealth University Massey Cancer Center was recently awarded a two-year, $2.391 million grant from the Virginia Tobacco Indemnification and Community Revitalization Commission (Tobacco Commission) to expand the breadth of the Center's community involvement and grow its state-of-the-art clinical research and cancer specialist delivery system. That delivery system is already in place in communities across Virginia, such as in the Lynchburg, Fredericksburg and Newport News areas.